PROFIL TERAPI DAN EVALUASI PERESEPAN PASIEN COVID-19 RAWAT INAP di RSU AL-ITTIHAD BLITAR

Tsamrotul Ilmi; Galuh Margareta Putri; Neni Probosiwi

doi:10.30591/pjif.v13i2.6610

PROFIL TERAPI DAN EVALUASI PERESEPAN PASIEN COVID-19 RAWAT INAP di RSU AL-ITTIHAD BLITAR

Tsamrotul Ilmi, Galuh Margareta Putri, Neni Probosiwi

Abstract

Coronavirus disease 2019 (COVID-19) merupakan penyakit yang disebabkan oleh SARS-CoV-2 dengan tingkat penularan dan mortalitas sangat tinggi. Tujuan penelitian adalah untuk mengetahui profil terapi dan evaluasi peresepan pasien Covid-19 rawat inap di RSU Al-Ittihad Blitar, Jawa Timur, berdasarkan acuan Protokol Tata Laksana COVID-19 edisi 2 bulan Januari 2021. Metode penelitian adalah non eksperimental dengan pendekatan deskriptif. Pengambilan data secara retrospektif, menggunakan data rekam medis pasien periode tahun 2021. Penelitian dilakukan pada bulan Mei–Juli 2022. Pengambilan sampel secara purposive sampling, didapatkan sampel sebanyak 100 pasien rawat inap COVID-19 selama periode tahun 2021. Hasil penelitian menunjukkan karakteristik pasien terbanyak adalah perempuan (55%), usia 40–59 tahun (47%), derajat keparahan sedang (87%), lama perawatan antara 1–10 hari (83%) dan pada akhir perawatan pasien sembuh (72%). Profil terapi obat berdasarkan kelas terapi terbanyak adalah obat saluran pernafasan (20%), obat saluran cerna (19%), vitamin (18%), antibiotik (9%), dan antivirus (7%). Berdasarkan jenis obat terbanyak yaitu suclarfat, omeprazole, N-Acetylsistein, vitamin C, dexametason, ambroxol, levofloxacin, Vitamin D, dan lain-lain. Hasil evaluasi peresepan obat yaitu 100% tepat obat, 96% tepat dosis, 100% tepat interval waktu, 92% tepat lama pemberian obat.

Keywords

Covid-19, Evaluasi peresepan, Profil terapi

Full Text:

References

BPOM, Informatorium obat Covid. 2020.

Y. Han and H. Yang, “The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): A Chinese perspective,” J. Med. Virol., vol. 92, no. 6, pp. 639–644, 2020, doi: 10.1002/jmv.25749.

Q. Li et al., “Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia,” N. Engl. J. Med., vol. 382, no. 13, pp. 1199–1207, 2020, doi: 10.1056/nejmoa2001316.

Kemenkes RI, “QnA : Pertanyaan dan Jawaban Terkait COVID-19,” Kemenkes RI, 2021. https://infeksiemerging.kemkes.go.id/uncategorized/qna-pertanyaan-dan- jawaban terkait -covid-19

N. F. Shalihah, “Kasus Kematian akibat Covid-19 Indonesia Nomor 7 di Dunia.,” Kompas.com, 2021. https://www.kompas.com/tren/read/2021/10/30/163000265/kasus-kematian- akibat-covid-19-indonesia-nomor-7- di-dunia? page=all

Gugus Covid-19, “Analisis Data Covid-19 Indonesia.,” Satuan Tugas Penanganan (Satgas) Covid-19, 2021. [Online]. Available: https://covid19.go.id/pengetahuan-umum/ analisis-data-covid-19-indonesia-update-20-juni-2021

S. M. Ilpaj and Nurwati, “Analisis Pengaruh Tingkat Kematian Akibat Covid-19 Terhadap Kesehatan Mental Masyarakat Di Indonesia.,” Focus J. Pekerj. Sos., vol. 3, p. 1, 2020, doi: https://doi.org/10.24198/focus.v3i1.28123.

E. Burhan, F. Isbaniah, A. D. Susanto, and T. Yoga, Diagnosis dan Penatalaksanaan Pneumonia COVID-19, vol. 1, no. 1. 2020. doi: 10.1331/JAPhA.2015.14093.

Kemenkes RI, “Protokol Tata Laksana Covid-19 Buku Saku,” Kementrian Kesehat., p. 105, 2021, [Online]. Available: https://www.papdi.or.id/pdfs/983/Buku Pedoman Tatalaksana COVID-19 5OP Edisi 3 2020.pdf

T. Ilmi et al., “Evaluation Of Antibiotic Use On Pneumonia Patients In Tulungagung Regional Indonesia ( PDPI , 2014 ), Infections Diseases Sociaty of America / American Thoracis Consensus Guidelines on the Managemen of Community-Acquired Pneumonia ,” vol. 1, no. 2, pp. 102–112, 2020.

S. Mukherjee and K. Pahan, “Is COVID-19 Gender-sensitive?,” J. Neuroimmune Pharmacol., vol. 16, no. 1, pp. 38–47, 2021, doi: 10.1007/s11481-020-09974-z.

N. U. En Masrika, M. Hasan, Y. Yusran, and S. Buyung, “Karakteristik Pasien COVID-19 di Rumah Sakit Umum Daerah Dr. H. Chasan Boesoirie,” JUMANTIK (Jurnal Ilm. Penelit. Kesehatan), vol. 7, no. 3, p. 255, 2022, doi: 10.30829/jumantik.v7i3.11676.

D. R. Karyono and A. L. Wicaksana, “Current prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia,” J. Community Empower. Heal., vol. 3, no. 2, p. 77, 2020, doi: 10.22146/jcoemph.57325.

Y. Cen et al., “Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019—a multi-centre observational study,” Clin. Microbiol. Infect., vol. 26, no. 9, pp. 1242–1247, 2020, doi: 10.1016/j.cmi.2020.05.041.

R. Elviani, C. Anwar, and R. Januar Sitorus, “Gambaran Usia Pada Kejadian Covid-19,” JAMBI Med. J. “Jurnal Kedokt. dan Kesehatan,” vol. 9, no. 1, pp. 204–209, 2021, doi: 10.22437/jmj.v9i1.11263.

B. D. Pepitasari and T. D. Anggraini, “Gambaran Tatalaksana Terapi Pada Pasien COVID-19 Terkonfirmasi di Rumah Sakit X Kota Surakarta Periode Maret â€“ Desember 2020,” Indones. J. Med. Sci., vol. 8, no. 2, pp. 119–126, 2021, doi: 10.55181/ijms.v8i2.321.

T. Jamini, “Gambaran Lama Hari Rawat Inap Pasien Covid-19 Berdasarkan Karakteristik Demografi, Klinis dan Hasil Laboratorium Pasien di Ruang Perawatan Covid-19 RSUD H. Boejasin Pelaihari Tahun 2021,” J. Penelit. UPR, vol. 1, no. 2, pp. 54–62, 2022, doi: 10.52850/jptupr.v1i2.4086.

N. M. Maharianingsih, I. K. Sudirta, and N. P. A. Suryaningsih, “Karakteristik Pasien dan Penggunaan Obat Pada Pasien Covid-19 Derajat Sedang Hingga Berat,” Indones. J. Pharm. Educ., vol. 2, no. 2, pp. 101–109, 2022, doi: 10.37311/ijpe.v2i2.13958.

H. Cartika, Y. Yusmaniar, A. Hakim Kurniawan, F. Hasbi, and D. Suryani, “Profile of Prescribing COVID -19 Drug Therapy in Inpatients At Jakarta Haji Hospital,” SANITAS J. Teknol. dan Seni Kesehat., vol. 13, no. 1, pp. 1–12, 2022, doi: 10.36525/sanitas.2022.1.

H. Ariyani, S. Fitriani, and S. Rahmah, “Profil Penggunaan Obat pada Pasien COVID-19 di Rumah Sakit Umum Daerah Ulin Banjarmasin,” J. Pharmascience, vol. 8, no. 2, p. 133, 2021, doi: 10.20527/jps.v8i2.11144.

S. De Flora, R. Balansky, and S. La Maestra, “Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19,” FASEB J., vol. 34, no. 10, pp. 13185–13193, 2020, doi: 10.1096/fj.202001807.

K. S. Sujana and M. Maulida, “Efektivitas N-Acetylsistein pada Pasien COVID-19,” Cermin Dunia Kedokt., vol. 48, no. 7, pp. 416–418, 2021, doi: 10.55175/cdk.v48i7.99.

M. Alkotaji, “Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2,” Int. J. Antimicrob. Agents, vol. 56, no. 6, p. 106192, 2020, doi: 10.1016/j.ijantimicag.2020.106192.

S. Mariam, “Evaluasi Kejadian Interaksi Obat Pada Pasien Rawat Inap Geriatri Penderita Gagal Jantung,” J. Farmamedika (Pharmamedica Journal), vol. 1, no. 1, pp. 28–33, 2016, doi: 10.47219/ath.v1i1.42.

A. A. Rahman, W. Maulidina, and E. D. Kosasih, “GAMBARAN TERAPI AWAL PADA PASIEN GERD (GASTROESOPHAGEAL REFLUX DISEASE) DI POLIKLINIK PENYAKIT DALAM RSUD dr. SOEKARDJO TAHUN 2018,” J. Kesehat. Poltekkes Kemenkes Ri Pangkalpinang, vol. 6, no. 2, p. 69, 2018, doi: 10.32922/jkp.v6i2.81.

W. A. Putri and T. D. Anggraini, “Gambaran Pengobatan Pasien Suspek Covid-19 Rawat Inap RS Brayat Minulya Surakarta Periode Maret–Oktober 2020,” Ejournal.Ijmsbm.Org, vol. 8, no. 2, pp. 111–118, 2021.

D. E. Bimantara, “Peran Vitamin C dalam Pengobatan Covid-19,” Major. J., vol. 9, no. 1, 2020.

R. Z. Cheng, “Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19)?,” Med. Drug Discov., no. 5, pp. 19–21, 2020, doi: https://doi.org/10.1016/j.medidd.2020.100028.

Y. Furuta, T. Komeno, and T. Nakamura, “Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase,” Proceedings of the Japan Academy Series B: Physical and Biological Sciences, vol. 93, no. 7. pp. 449–463, 2017. doi: 10.2183/pjab.93.027.

B. N. Williamson et al., “Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2,” Nature, vol. 585, no. 7824, pp. 273–276, 2020, doi: 10.1038/s41586-020-2423-5.

S. Ardyati, N. U. Kurniawan, and E. Darmawan, “Steroids Effect as Adjuvant Therapy toward Length of Stay and Clinical Symptoms in Pediatric with Pneumonia,” Indones. J. Clin. Pharm., vol. 6, no. 3, pp. 181–189, 2017, doi: 10.15416/ijcp.2017.6.3.181.

P. Horby, W. S. Lim, J. Emberson, and M. Mafham, “Effect of dexamethasone in hospitalized patients with COVID-19–preliminary report,” MedRxiv, 2020, [Online]. Available: https://www.medrxiv.org/content/10.1101/2020.06.22.20137273.abstract

H. Cartika, A. H. Kurniawan, F. Hasbi, and D. Suryani, “PROFILE OF PRESCRIBING COVID-19 DRUG THERAPY IN INPATIENTS AT Jurusan Farmasi , Politeknik Kesehatan Kemenkes Jakarta II Jl . Percetakan Negara No . 23 Jakarta Pusat , 10560 , Indonesia PENDAHULUAN SARS-CoV-2 , penyebab Penyakit Coronavirus 2019 ( COVID-1,” vol. 13, no. 1, pp. 1–11, 2022.

F. Oktarina, A. M. Ulfa, and M. P. Angin, “Evaluasi Rasionalitas Penggunaan Obat Covid-19 di Rawat Inap Rumah Sakit Imanuel Bandar Lampung Tahun 2020,” J. Mandala Pharmacon Indones., vol. 7, no. 2, pp. 237–250, 2021, [Online]. Available: www.jurnal-pharmaconmw.com/jmpi

J. Sultana, P. M. Cutroneo, S. Crisafulli, G. Puglisi, G. Caramori, and G. Trifirò, “Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines,” Drug Saf., vol. 43, no. 8, pp. 691–698, 2020, doi: 10.1007/s40264-020-00976-7.

M. H. Ahmed and A. Hassan, “Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review,” SN Compr. Clin. Med., vol. 2, no. 12, pp. 2637–2646, 2020, doi: 10.1007/s42399-020-00610-8.

DOI: https://doi.org/10.30591/pjif.v13i2.6610